Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Polycystic Kidney Disease 2 (Autosomal Dominant) (PKD2) (4th Cytoplasmic Loop) antibody
4th Cytoplasmic Loop
Alternatives Immunohistochemistry (IHC), Western Blotting (WB)
|10 references available|
|Price||454.67 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 7 to 8 Business Days|
|Alternative name||polycystic kidney disease 2 protein (PKD2, Polycystin-2)|
|Immunogen||A synthetic peptide from the 4th cytoplasmic loop of human Polycystic kidney disease 2 protein (PKD2, Polycystin-2, Polycystwin) conjugated to an immunogenic carrier protein was used as the immunogen.|
|Description||FUNCTION: Functions as a calcium permeable cation channel. PKD1 and PKD2 may function through a common signaling pathway that is necessary for normal tubulogenesis. SUBUNIT: Interacts with PKD1. PKD1 requires the presence of PKD2 for stable expression. Interacts with CD2AP. SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein. TISSUE SPECIFICITY: Strongly expressed in ovary, fetal and adult kidney, testis, and small intestine. Not detected in peripheral leukocytes. DISEASE: Defects in PKD2 are the cause of polycystic kidney disease autosomal dominant type 2 (ADPKD2). ADPKD2 represents approximately 15% of the cases of ADPKD, a common genetic disease affecting about 1:400 to 1:1000 individuals. ADPKD is characterized by progressive formation and enlargement of cysts in both kidneys, typically leading to end-stage renal disease in adult life. Cysts also occurs in the liver and other organs. ADPKD2 is clinically milder than ADPKD1 but it has a deleterious impact on overall life expectancy. Also known as: PKD2, Polycystin-2, Autosomal dominant polycystic kidney disease type II protein, Polycystwin, R48321.|
|Specificity||Appears to be specific for PKD2.|
|Application Notes||IHC, WB. A dilution of 1 : 300 to 1 : 2000 is recommended. The optimal dilution should be determined by the end user. Not yet tested in other applications.|
|Storage||Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.|
|Restrictions||For Research Use only|
Mochizuki, Wu, Hayashi et al.: "PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein." in: Science (New York, N.Y.), Vol. 272, Issue 5266, pp. 1339-42, 1996 (PubMed).
Schneider, Rodriguez, Nomura et al.: "A gene similar to PKD1 maps to chromosome 4q22: a candidate gene for PKD2." in: Genomics, Vol. 38, Issue 1, pp. 1-4, 1997 (PubMed).
Hayashi, Mochizuki, Reynolds et al.: "Characterization of the exon structure of the polycystic kidney disease 2 gene (PKD2)." in: Genomics, Vol. 44, Issue 1, pp. 131-6, 1997 (PubMed).
Veldhuisen, Saris, de Haij et al.: "A spectrum of mutations in the second gene for autosomal dominant polycystic kidney disease (PKD2)." in: American journal of human genetics, Vol. 61, Issue 3, pp. 547-55, 1997 (PubMed).
Torra, Viribay, Telleruia et al.: "Seven novel mutations of the PKD2 gene in families with autosomal dominant polycystic kidney disease." in: Kidney international, Vol. 56, Issue 1, pp. 28-33, 1999 (PubMed).
Watnick, He, Wang et al.: "Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations." in: Nature genetics, Vol. 25, Issue 2, pp. 143-4, 2000 (PubMed).
Lehtonen, Ora, Olkkonen et al.: "In vivo interaction of the adapter protein CD2-associated protein with the type 2 polycystic kidney disease protein, polycystin-2." in: The Journal of biological chemistry, Vol. 275, Issue 42, pp. 32888-93, 2000 (PubMed).
Stayner, Zhou: "Polycystin channels and kidney disease." in: Trends in pharmacological sciences, Vol. 22, Issue 11, pp. 543-6, 2001 (PubMed).
Olsen, Blagoev, Gnad et al.: "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks." in: Cell, Vol. 127, Issue 3, pp. 635-48, 2006 (PubMed).
Molina, Horn, Tang et al.: "Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, Issue 7, pp. 2199-204, 2007 (PubMed).
|Hosts||Rabbit (46), Goat (3)|
|Reactivities||Human (44), Mouse (Murine) (40), Rat (Rattus) (36), Cow (Bovine) (19), Chicken (18), Dog (Canine) (18)|
|Applications||ELISA (29), Western Blotting (WB) (27), Immunofluorescence (IF) (22), Immunohistochemistry (IHC) (4), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)) (4), Immunohistochemistry (Formalin-fixed Sections) (IHC (f)) (3), Immunocytochemistry (ICC) (2), Immunoelectron Microscopy (IEM) (1), Immunohistochemistry (Frozen Sections) (IHC (fro)) (1), Immunoprecipitation (IP) (1)|
|Conjugates||Alexa Fluor 350 (1), Alexa Fluor 488 (1), Alexa Fluor 555 (1), Alexa Fluor 647 (1), Biotin (1), Cy3 (1), Cy5 (1), Cy5.5 (1), Cy7 (1), FITC (1), Gold (1), HRP (1), PE (1), PE,Cy3 (1), PE,Cy5 (1), PE,Cy5.5 (1), PE,Cy7 (1)|
|Epitopes||C-Term (29), pSer812,C-Term (3), pSer876,C-Term (3), C-Term,AA 873-903 (1), Internal Region (1), pSer876 (1)|